Elsa Mondou
Research Subjects
Elsa Mondou has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Kim Hanna
Grifols Therapeut LLC, Res Triangle Pk, NC USA
2 shared publicationsAleksandar Sretenović
Univ Childrens Hosp, Belgrade, Serbia
1 shared publication- Antonio Páez
Grifols, Barcelona Spain
1 shared publication - David Vilardell
Grifols Bioscience Research Group, Avinguda de la Generalitat, 152, Parc empresarial Can Sant Joan, 08174 Sant Cugat del Vallès, Spain
1 shared publication - Deborah Gelinas
Scientific and Medical Affairs, Grifols, 79 TW Alexander Drive 4101 Research Commons, Research Triangle Park, NC 27709, USA
1 shared publication Djordje Gajdobranski
Univ Novi Sad, Inst Hlth Protect Children & Youth, Fac Med, Novi Sad, Serbia
1 shared publication
Latest Publications
- Open Access
- 23 July 2024
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 59 (11) , 161639
A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery
- 23 July 2024
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 59 (11) , 161639
Open AccessA Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery
- Open Access
- 7 January 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 104, 108472
Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases
- 7 January 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 104, 108472
Open AccessPharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases
- Open Access
- 1 November 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 406, 116428
Myasthenia gravis: Historical achievements and the “golden age” of clinical trials
- 1 November 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 406, 116428
Open AccessMyasthenia gravis: Historical achievements and the “golden age” of clinical trials
- Open Access
- 1 June 2018
- Published by Taylor & Francis in Clinical Pharmacology: Advances and Applications
- Vol. ume 10, 79-88
Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified
Background: Rabies immune globulin (RIG) and vaccination series are necessary for postexposure prophylaxis. A new formulation of RIG (human) purified by caprylate/chromatography (RIG-C) was evaluated. Trial registration: ClinicalTrials.gov identifier: NCT02139657. Materials and methods: This open-label, single-arm study in healthy subjects evaluated neutralizing rabies antibody concentrations produced from a single 20 IU/kg intramuscular (IM) dose of RIG-C as measured by rapid fluorescent focus inhibition test (50% neutralization endpoint) 1-hour postdose and on days 1, 2, 4, 6, 8, 10, 14, 18, and 21. Results: Twelve subjects were enrolled into the study. No discontinuations, serious adverse events (AEs), or treatment-emergent clinically significant changes in laboratory parameters were observed. All AEs resolved and were mild except 1 moderate AE of oropharyngeal pain. Injection site pain (4 subjects) was most commonly reported. RIG-C produced a rapid increase in neutralizing rabies antibody: mean value 0.113 IU/mL at 24 hours after IM injection, peak on day 4 (0.132 IU/mL), persisting through day 21 (0.116 IU/mL). The mean reciprocal titer was 11.5 by day 2; the peak value of 12.1 was achieved on day 4; and a mean value ≥10.6 was maintained through day 21. Conclusion: RIG-C was well tolerated and provided neutralizing rabies antibodies, which combined with vaccine series after rabies exposure, should result in effective prophylaxis per World Health Organization/Centers for Disease Control and Prevention guidelines.
- 1 June 2018
- Published by Taylor & Francis in Clinical Pharmacology: Advances and Applications
- Vol. ume 10, 79-88
Open AccessSafety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified
Background: Rabies immune globulin (RIG) and vaccination series are necessary for postexposure prophylaxis. A new formulation of RIG (human) purified by caprylate/chromatography (RIG-C) was evaluated. Trial registration: ClinicalTrials.gov identifier: NCT02139657. Materials and methods: This open-label, single-arm study in healthy subjects evaluated neutralizing rabies antibody concentrations produced from a single 20 IU/kg intramuscular (IM) dose of RIG-C as measured by rapid fluorescent focus inhibition test (50% neutralization endpoint) 1-hour postdose and on days 1, 2, 4, 6, 8, 10, 14, 18, and 21. Results: Twelve subjects were enrolled into the study. No discontinuations, serious adverse events (AEs), or treatment-emergent clinically significant changes in laboratory parameters were observed. All AEs resolved and were mild except 1 moderate AE of oropharyngeal pain. Injection site pain (4 subjects) was most commonly reported. RIG-C produced a rapid increase in neutralizing rabies antibody: mean value 0.113 IU/mL at 24 hours after IM injection, peak on day 4 (0.132 IU/mL), persisting through day 21 (0.116 IU/mL). The mean reciprocal titer was 11.5 by day 2; the peak value of 12.1 was achieved on day 4; and a mean value ≥10.6 was maintained through day 21. Conclusion: RIG-C was well tolerated and provided neutralizing rabies antibodies, which combined with vaccine series after rabies exposure, should result in effective prophylaxis per World Health Organization/Centers for Disease Control and Prevention guidelines.